Sonoma Pharmaceuticals, Inc. (SNOA) [Rocket]

Date Filed	Type	Description
02/15/2021	GN	BREAKING ALERT: ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Sonoma Pharmaceuticals, Inc. Investors with Losses to Inquire About Securities Class Action Investigation – SNOA
02/02/2021	GN	Sonoma Pharmaceuticals, Inc.: Company Investigated by the Portnoy Law Firm
12/19/2020	GN	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sonoma Pharmaceuticals, Inc. - SNOA
12/07/2020	GN	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sonoma Pharmaceuticals, Inc. - SNOA
12/02/2020	GN	ROSEN, RESPECTED INVESTOR COUNSEL, Continues to Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. – SNOA
11/30/2020	GN	SONOMA PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. is Investigating Sonoma Pharmaceuticals, Inc. on Behalf of Sonoma Stockholders and Encourages Investors to Contact the Firm
11/30/2020	GN	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sonoma Pharmaceuticals, Inc. – SNOA
11/25/2020	GN	Sonoma Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm
02/27/2020	GN	Sonoma Pharmaceuticals Announces Asset Purchase Agreement with Middle East Partner MicroSafe Group
02/14/2020	GN	Sonoma Pharmaceuticals Reports Third Quarter FY 2020 Financial Results
11/29/2019	GN	Sonoma Pharmaceuticals Announces Closing of $1.6 Million Public Offering of Common Stock
11/26/2019	GN	Sonoma Pharmaceuticals Announces Pricing of Approximately $1.6 million Public Offering of Common Stock
11/25/2019	GN	Sonoma Pharmaceuticals Announces Proposed Public Offering of Common Stock